Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing.
40 
Let's personalize your content